Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Regeneron Q3 2026 Earnings Analysis cover art

Regeneron Q3 2026 Earnings Analysis

Regeneron Q3 2026 Earnings Analysis

Listen for free

View show details
About this listen
More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown, where we turn dense earnings calls into conversations you'd actually want to have with a friend. I'm Alex.

**JORDAN:** And I'm Jordan. Alex, we've got a big one today.

**ALEX:** We really do — Regeneron, ticker REGN, reporting Q3 2026 results. But before we jump in, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Important stuff. Okay, so Alex, let's set the scene — the stock popped nearly 13% on this print. That's not a small move for a company this size.

**ALEX:** No kidding. And when you look at the numbers, it's easy to see why. Total revenue grew 36% year-over-year to $5.1 billion. Non-GAAP earnings per share jumped 70% to $20.07. This is the third straight quarter of double-digit growth on both the top and bottom line.

**JORDAN:** And it wasn't just one product carrying the load. Dupixent, EYLEA HD, and Libtayo — their three biggest commercial brands — each hit all-time-high quarterly sales. Two quarters in a row, actually.

**ALEX:** Let's break those down one at a time, because the Dupixent number alone is wild. Global sales hit $6.5 billion, up 35% at constant currency. In the U.S. specifically, sales crossed $5 billion for the first time ever.

**JORDAN:** For a drug that's approaching its tenth year on the market, that's genuinely remarkable. Most blockbuster drugs plateau or start fading by year ten — Dupixent is accelerating. It's the leading biologic in eight of its nine approved indications.

**ALEX:** Then there's EYLEA HD, the next-gen eye medicine. U.S. sales hit $699 million, up 62% year-over-year, and it now makes up almost two-thirds of their retinal franchise. Physician demand grew 20% sequentially.

**JORDAN:** Though I'll note — the older EYLEA formulation is declining fast, down 41%, as biosimilar competition eats into that market. So this is really a story of EYLEA HD cannibalizing its predecessor successfully, which is the right problem to have.

**ALEX:** Right, it's a managed transition, not just pure growth. And then Libtayo, their cancer immunotherapy — $550 million globally, up 51%. It's now running at an annual pace of about $2.2 billion.

**JORDAN:** Now here's the part that I think got Wall Street really excited — the Sanofi relationship. Regeneron finished repaying its development cost balance to Sanofi, which means for the first time, they're collecting their FULL share of Dupixent collaboration profits. No more clawbacks eating into the number.

**ALEX:** And on top of that, they announced an expanded alliance — four next-generation long-acting antibodies targeting the same pathways that made Dupixent a hit. Regeneron gets a $1 billion upfront payment landing in Q4, and going forward, they split both R&D costs and profits 50/50 with Sanofi. That's a much better deal structurally than before.

**JORDAN:** CEO Leonard Schleifer called it leading "the next era of type 2 inflammation medicines." And CSO George Yancopoulos made an interesting point in the Q&A — he argued their antibodies are "naturally derived" from their humanized mouse platform, versus competitors using heavily engineered older antibodies, which historically have more immune and safety issues.

**ALEX:** That's classic Regeneron — leaning on their genetics-driven science story. Speaking of which, the CIDEB program in NASH, or fatty liver disease, might be the most eye-popping pipeline data point this quarter.

**JORDAN:** Yeah, this one's worth pausing on. Regeneron's genetics database found people with a naturally occurring loss-of-function in the CIDEB gene have dramatically lower rates of fatty liver di

This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet